Ligand, Glaxo drug gets European approval

In December, a European advisory committee recommended approving the drug. It was discovered by Ligand, is already approved in the U.S. as Promacta. Ligand's licensing partner GlaxoSmithKline handled the European application.

Thrombocytopenia purpura is rare blood condition that involves low platelet counts, making it more difficult for blood to clot.